Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFα Antagonist

Trial Profile

Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFα Antagonist

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Gerilimzumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Bird Rock Bio
  • Most Recent Events

    • 16 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 16 Jan 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 16 Jan 2018 Planned initiation date changed from 1 Nov 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top